Trials / Withdrawn
WithdrawnNCT04874831
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | domatinostat in combination with avelumab | domatinostat tablets and avelumab infusion |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2025-09-01
- Completion
- 2025-09-01
- First posted
- 2021-05-06
- Last updated
- 2021-11-18
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04874831. Inclusion in this directory is not an endorsement.